Rapid-acting insulin compositions with triphosphate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current commercial insulin compositions have slow uptake and onset of action, which fails to rapidly match carbohydrate absorption profiles, leading to hyperglycemia during the early postprandial period and potential late hypoglycemia or weight gain.
Innovation Solution
A pharmaceutical insulin composition containing insulin and triphosphate, without saccharide multimers or EDTA, with triphosphate concentrations between 10 to 30 mM, and optionally including zinc and a tonicity agent like glycerol, to enhance rapid insulin uptake and onset of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional insulin compositions are used, then insulin is administered to patients, but the uptake and onset of action are slow, resulting in hyperglycemia during the early postprandial period
Solution Approach 1:
The patent changes the chemical composition parameters of the insulin formulation by incorporating triphosphate at concentrations of 10-30 mM, which fundamentally alters the pharmacokinetic parameters of insulin absorption and onset of action
Solution Approach 2:
The patent creates a composite insulin formulation by combining insulin with triphosphate and optionally zinc, where the composite material exhibits enhanced absorption characteristics compared to conventional insulin formulations
2Duration of action of moving object
If conventional rapid-acting insulin analogs are used, then insulin activity is provided, but the time-action profile does not sufficiently match carbohydrate absorption, leading to late postprandial hypoglycemia
Solution Approach 1:
The patent modifies the duration and shape of the insulin action curve by incorporating triphosphate, which accelerates both the onset and the overall time-action profile to better synchronize with carbohydrate absorption kinetics
3Speed
If triphosphate is added to insulin composition, then uptake speed increases, but composition complexity increases
Solution Approach 1:
The patent manages composition complexity by defining specific concentration ranges for triphosphate (10-30 mM) and optional zinc (0.2-5 mM), transforming a potentially complex formulation problem into a controlled parameter optimization
Data Source
AI summary
The invention is a composition of insulin or insulin analog that has faster pharmacokinetic action than commercial formulations of rapid-onset insulin analog products.